Funder
National Natural Science Foundation of China
The Capital's Funds for Health Improvement and Research
The Beijing Municipal Administration of Hospitals Incubating Program
Wu Jieping Medical Foundation
Clinical Research Fund for Distinguished Young Scholars of Beijing Cancer Hospital
Guangzhou Life oasis public service center Research and exchange program in the field of health
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. American Cancer Society Lung cancer survival rates: 5-year survival rates for lung cancer. https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html
2. Rittberg R, Banerji S, Kim JO, Rathod S, Dawe DE. Treatment and prevention of brain metastases in small cell lung cancer. Am J Clin Oncol. 2021;44:629–38.
3. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20:4665–72.
4. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9.
5. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39.